Insider Purchases: Inside the Buy
Tag: Eli Lilly
🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.
When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.
🎨 Adobe (ADBE) Stock Analysis: Why Eli Lilly CEO David Ricks Just Bought $1.9 Million of Adobe Stock
Wall Street says AI threatens Adobe. The numbers tell a different story. Revenue keeps hitting records, AI recurring revenue has tripled, valuation has collapsed to multi-year lows, and Eli Lilly CEO David Ricks just invested another $1.9 million of his own money. Here's why Adobe may deserve another look.
Elite Buys Ely: Should You Buy Lilly’s Stock Too?
Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?